15 Oct How to Manage Allergen Segregation in Production
A single unlabelled allergen carry-over can turn an otherwise compliant blend into a costly hold, withdrawal or customer complaint. Knowing how to manage allergen segregation means controlling the ingredient from supplier approval through receipt, storage, dispensing, manufacture, cleaning and final release. For supplement and functional food businesses, the system must reflect actual cross-contact risk rather than relying on warehouse labels alone.
Start with an allergen risk assessment
Allergen segregation should begin before a material reaches site. Build an allergen register that identifies each raw material, its allergen status, potential cross-contact statements, country of origin, processing aids and packaging format. The assessment should cover the recognised regulated allergens relevant to the market in which the finished product will be sold, as well as any customer-specific exclusions.
For nutraceutical operations, the highest-risk materials may include milk-derived proteins, soya lecithin, egg derivatives, wheat-based carriers, crustacean-derived glucosamine and fish oils. However, risk is not limited to obvious sources. A botanical extract may be supplied on a maltodextrin carrier; a flavour system may contain milk derivatives; and a compound purchased as allergen-free may be packed on a line handling other allergenic materials.
Classify materials according to their likely impact if cross-contact occurs. The classification should consider the allergen itself, dustiness, particle size, handling frequency, open versus closed processing, shared equipment and the intended finished-product claim. This allows controls to be proportionate. A sealed drum of encapsulated fish oil presents a different operational risk from an open sack of milk protein isolate being weighed into a blend.
Put supplier information under document control
Supplier approval is a core allergen control, not simply a purchasing exercise. Obtain current specifications, allergen declarations, certificates of analysis where applicable, technical data and statements covering possible cross-contact. These documents should be reviewed against the material specification approved by quality and product development teams.
Where a material is declared free from a particular allergen, establish what that declaration means. It may refer to formulation only, a dedicated production area, validated cleaning between campaigns or an absence of intentional addition. These are not equivalent assurances. Procurement teams should avoid treating a broad allergen statement as evidence of a defined manufacturing control programme.
Changes in source, processing site, carrier, packaging or manufacturing method should trigger a reassessment before stock is accepted for routine use. This is especially relevant for materials with variable supply chains, including plant extracts, fruit powders and proteins. A formal change-control process helps prevent an updated supplier declaration being missed after the ingredient has already entered production.
Design storage around physical separation
Effective allergen segregation in storage requires clear physical and procedural boundaries. Allergenic materials should be identified at receipt, placed into designated locations and protected from damage or leakage. Labels should be legible from the point of handling and should state the allergen status in a consistent format understood by warehouse and production personnel.
Dedicated racking, bays or clearly marked zones are often appropriate for high-risk powders and materials handled in open format. Where full physical separation is not practicable, use location controls that prevent allergenic stock being stored directly above non-allergenic materials. This reduces the consequences of a damaged bag, loose powder or spill during stock movement.
Keep materials sealed in their original packaging until needed. Once a pack is opened, use secure, labelled secondary containment and record the opening date, batch number and allergen status. Rework, retained samples and part-used materials require the same discipline. They are frequent weak points because they move outside normal stock flows and may be returned to storage without adequate identification.
Control dispensing and production sequencing
The point at which materials are opened, weighed and transferred usually creates the greatest cross-contact risk. A well-designed dispensing area should have defined allergen handling procedures, suitable extraction where dust is generated, cleanable surfaces and sufficient space to avoid multiple open materials being handled together.
Schedule production to minimise cleaning burden and risk. A common approach is to run non-allergen products first, followed by products containing one or more allergens, with the highest-risk or most difficult-to-clean materials last. This approach is useful, but it is not a substitute for validated cleaning. Production sequence depends on the equipment, formulation, particle behaviour and allergen type. Sticky powders, fine protein dust and oil-based materials can each require different controls.
Use dedicated utensils, scoops, weighing vessels, hoses and personal protective equipment where risk justifies it. A colour-coded system can help, provided colours are documented and staff do not rely on colour alone. Equipment must still carry an identifiable status and be stored to prevent accidental use on another line.
For contract manufacturers handling many customer formulations, it may be appropriate to dedicate specific rooms, lines or campaign windows to particular allergen groups. This can reduce operational flexibility, but it may also reduce cleaning time, testing requirements and the risk of incorrectly labelled finished goods. The right balance depends on throughput, site layout and customer commitments.
Validate cleaning rather than assuming it works
Cleaning is the control that supports shared-equipment manufacturing. A visual inspection is necessary, but it cannot demonstrate the removal of allergenic residues that may remain in seals, transfer points, filters, dead legs or difficult-to-access surfaces.
Cleaning validation should be based on a risk assessment and should reflect the most challenging realistic conditions. Consider the allergen, product matrix, equipment geometry, cleaning method and the next product manufactured. Dry cleaning may be suitable for many powder operations, while wet cleaning may be required for oil or paste residues. Introducing water to a dry process, however, can create microbiological and operational issues, so the method must fit the facility.
Verification can include documented pre-operational inspections, protein swabs, allergen-specific lateral-flow devices or laboratory analysis. The appropriate method depends on the allergen and the sensitivity required. Testing is valuable, but it should confirm a controlled process rather than compensate for poor cleaning design. Establish clear acceptance criteria, investigation requirements and re-cleaning actions before routine use.
Train people for the decisions they make
Allergen control fails when a temporary operator uses the wrong scoop, a cleaner overlooks an extractor duct or a warehouse colleague relocates a part-used bag for convenience. Training should therefore explain the reason behind each control, not merely the instruction.
Staff who receive goods need to recognise declaration discrepancies and damaged packaging. Warehouse teams need to understand storage status and spill procedures. Production operators need to know line-clearance requirements, equipment identification and the escalation route when an error occurs. Quality personnel need sufficient technical understanding to assess supplier evidence, cleaning records and deviations.
Competence should be checked in practice. Observations on the shop floor, refresher training after changes and targeted retraining following deviations are more useful than relying only on signed attendance sheets.
Maintain traceability and release discipline
A controlled allergen programme depends on records that connect every finished batch to its component materials, production area, equipment, cleaning status and labels. Batch documentation should make it possible to confirm that the correct approved material was used and that allergen information was carried through to finished-product specification and artwork approval.
Line clearance before packing deserves particular attention. The previous product, obsolete labels, printed packaging, loose components and work-in-progress must be removed or reconciled before the next run starts. An allergen-safe formulation can still become a serious incident if it is packed in the wrong label or if residual product enters the next batch.
Deviation procedures should distinguish between a contained procedural error and a credible cross-contact event. Hold affected stock immediately, assess the materials and equipment involved, review cleaning and production records, and decide whether testing, relabelling, rework or disposal is justified. Decisions should be evidence-led and documented, particularly where a product is supplied to brand owners with their own allergen policies.
Review the system when operations change
Allergen segregation is not a one-off quality project. Review the risk assessment when adding a new ingredient, changing warehouse layout, commissioning equipment, onboarding a supplier, introducing new packaging or accepting a customer formulation. Internal audits should follow the physical flow of materials rather than only reviewing paperwork in an office.
For B2B ingredient supply, clear allergen documentation and disciplined handling protect both the supplier and the customer’s downstream manufacturing process. The most effective programme is practical enough for daily operations, specific enough for each material and continuously tested against how people actually receive, store and process ingredients.